KDR and hematopoietic and lymphoid system neoplasm: These genes have been described as oncogenes, coding for vascular endothelial growth factor receptor 2 [57,74,75], promoting cell survival by activating NF-kb [76,77], activating downstream MAPK/ERK signaling, inhibiting p53 and activating cMyc [78,79], and promoting cell growth in hematological neoplasms by activating LINC00478/miR-125b [80].